Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs

Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs

Purpose: To accurately ascertain the frequency of pathogenic germline variants (PGVs) in a pan-cancer patient population with universal genetic testing and to assess the economic impact of receiving genetic testing on healthcare costs. Methods: In this prospective study, germline genetic testing usi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Adrienne T. Perkins, Derrick Haslem, Jessica Goldsberry, Katherine Shortt, Laura Sittig, Sharanya Raghunath, Christopher Giauque, Shawnee Snow, Gail Fulde, Bryce Moulton, David Jones, Lincoln Nadauld
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
hereditary cancer
healthcare costs
precision oncology
pathogenic germline variants
germline testing
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/caf8a4a6468242518ce58803bfb254a7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/caf8a4a6468242518ce58803bfb254a7

Documents similaires